What is KESTRA MED TECHNOLOGIES LTD's earnings per share (EPS)?

KESTRA MED TECHNOLOGIES LTD (KMTS) reported diluted earnings per share of $-2.43 for fiscal year 2026. This represents a 52.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

KESTRA MED TECHNOLOGIES LTD Financials

KMTS

Source SEC Filings (10-K/10-Q) Data as of Apr 30, 2026 Currency USD FYE April

This page shows KESTRA MED TECHNOLOGIES LTD (KMTS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KMTS FY2025 2026-07-14

Commercialization spending is outrunning improved unit economics, while a large recapitalization currently funds the operating gap.

Between FY2024 and FY2025, gross margin jumped from 1.3% to 40.5%, yet the operating loss still widened because selling and administrative costs expanded faster than gross profit. More revealing, equity swung from -$216.5M to $184.2M despite continued cash burn, so the stronger balance sheet reflects recapitalization rather than profits finally converting to cash.

The business now looks materially healthier at the gross-profit line than a year earlier: direct economics improved sharply, which suggests the problem is no longer only product cost. The bottleneck is overhead absorption—commercial infrastructure is still too heavy for the current revenue base.

Liquidity is currently financing-backed, not self-funded: cash of $201.2M and a current ratio of 6.8x sit alongside operating cash flow of -$77.6M. With long-term debt at $41.5M, the near-term issue is less balance-sheet pressure than whether improved gross profit can eventually carry the fixed cost structure.

Financial Health Signals

Financial Health Score 48/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of KESTRA MED TECHNOLOGIES LTD's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Safe

4.55

KESTRA MED TECHNOLOGIES LTD scores 4.55, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($1.2B) relative to total liabilities ($98.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral

5/9

KESTRA MED TECHNOLOGIES LTD passes 5 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Low Quality

0.62x

For every $1 of reported earnings, KESTRA MED TECHNOLOGIES LTD generates $0.62 in operating cash flow (-$81.7M OCF vs -$131.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-17.9x

KESTRA MED TECHNOLOGIES LTD earns $-17.9 in operating income for every $1 of interest expense (-$134.7M vs $7.5M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$95.1M

YoY+59.0%

KESTRA MED TECHNOLOGIES LTD generated $95.1M in revenue in fiscal year 2026. This represents an increase of 59.0% from the prior year.

EBITDA

-$126.0M

YoY-28.1%

KESTRA MED TECHNOLOGIES LTD's EBITDA was -$126.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 28.1% from the prior year.

Net Income

-$131.6M

YoY-15.6%

KESTRA MED TECHNOLOGIES LTD reported -$131.6M in net income in fiscal year 2026. This represents a decrease of 15.6% from the prior year.

EPS (Diluted)

$-2.43

YoY+52.6%

KESTRA MED TECHNOLOGIES LTD earned $-2.43 per diluted share (EPS) in fiscal year 2026. This represents an increase of 52.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$116.6M

YoY-16.0%

KESTRA MED TECHNOLOGIES LTD generated -$116.6M in free cash flow in fiscal year 2026, representing cash available after capex. This represents a decrease of 16.0% from the prior year.

Cash & Debt

$99.7M

YoY-50.4%

KESTRA MED TECHNOLOGIES LTD held $99.7M in cash against $42.6M in long-term debt as of fiscal year 2026.

Dividends Per Share

N/A

Shares Outstanding

59M

YoY+14.1%

KESTRA MED TECHNOLOGIES LTD had 59M shares outstanding in fiscal year 2026. This represents an increase of 14.1% from the prior year.

Margins & Returns

Gross Margin

51.4%

YoY+10.9pp

KESTRA MED TECHNOLOGIES LTD's gross margin was 51.4% in fiscal year 2026, indicating the percentage of revenue retained after direct costs. This is up 10.9 percentage points from the prior year.

Operating Margin

-141.6%

YoY+36.2pp

KESTRA MED TECHNOLOGIES LTD's operating margin was -141.6% in fiscal year 2026, reflecting core business profitability. This is up 36.2 percentage points from the prior year.

Net Margin

-138.4%

YoY+51.9pp

KESTRA MED TECHNOLOGIES LTD's net profit margin was -138.4% in fiscal year 2026, showing the share of revenue converted to profit. This is up 51.9 percentage points from the prior year.

Return on Equity

-50.7%

YoY+11.1pp

KESTRA MED TECHNOLOGIES LTD's ROE was -50.7% in fiscal year 2026, measuring profit generated per dollar of shareholder equity. This is up 11.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$19.5M

YoY+24.5%

KESTRA MED TECHNOLOGIES LTD invested $19.5M in research and development in fiscal year 2026. This represents an increase of 24.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$34.9M

YoY+52.1%

KESTRA MED TECHNOLOGIES LTD invested $34.9M in capex in fiscal year 2026, funding long-term assets and infrastructure. This represents an increase of 52.1% from the prior year.

KMTS Income Statement

Metric	FY26	FY25	FY24
Revenue	$95.1M+59.0%	$59.8M+115.1%	$27.8M
Cost of Revenue	$46.3M+29.9%	$35.6M+29.7%	$27.5M
Gross Profit	$48.9M+101.8%	$24.2M+6587.8%	$362K
R&D Expenses	$19.5M+24.5%	$15.7M+1.0%	$15.5M
SG&A Expenses	$164.1M+42.8%	$114.9M+64.3%	$69.9M
Operating Income	-$134.7M-26.7%	-$106.4M-25.1%	-$85.1M
Interest Expense	$7.5M-2.4%	$7.7M+24.1%	$6.2M
Income Tax	$294K+117.8%	$135K+462.5%	$24K
Net Income	-$131.6M-15.6%	-$113.8M-20.9%	-$94.1M
EPS (Diluted)	$-2.43+52.6%	$-5.13	$-5.07

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Revenue	$28.6M+16.6%	$24.6M+8.8%	$22.6M+16.5%	$19.4M+12.4%	$17.2M+14.2%	$15.1M+2.6%	$14.7M+15.1%	$12.8M
Cost of Revenue	$13.0M+11.2%	$11.6M+4.5%	$11.1M+5.9%	$10.5M+9.6%	$9.6M+12.4%	$8.5M-3.8%	$8.9M+3.5%	$8.6M
Gross Profit	$15.7M+21.5%	$12.9M+13.0%	$11.4M+29.1%	$8.9M+16.0%	$7.6M+16.6%	$6.5M+12.3%	$5.8M+38.8%	$4.2M
R&D Expenses	$5.6M+13.3%	$5.0M+1.9%	$4.9M+21.9%	$4.0M-25.7%	$5.4M+60.6%	$3.4M-4.4%	$3.5M+3.1%	$3.4M
SG&A Expenses	$49.4M+15.7%	$42.7M+11.5%	$38.3M+13.6%	$33.7M-33.2%	$50.5M+112.1%	$23.8M+10.9%	$21.5M+11.6%	$19.2M
Operating Income	-$39.3M-13.2%	-$34.8M-9.5%	-$31.8M-10.0%	-$28.9M+40.1%	-$48.2M-134.0%	-$20.6M-7.7%	-$19.1M-3.8%	-$18.4M
Interest Expense	$1.8M-2.3%	$1.9M-0.7%	$1.9M-0.6%	$1.9M+8.6%	$1.8M-1.3%	$1.8M-23.0%	$2.3M+23.6%	$1.9M
Income Tax	$192K+448.6%	$35K+2.9%	$34K+3.0%	$33K-67.6%	$102K+466.7%	$18K+125.0%	$8K+14.3%	$7K
Net Income	-$38.8M-13.7%	-$34.2M-4.2%	-$32.8M-26.9%	-$25.8M+50.4%	-$52.1M-142.0%	-$21.5M-5.6%	-$20.4M-2.4%	-$19.9M
EPS (Diluted)	N/A	$-0.61+4.7%	$-0.64-28.0%	$-0.50	N/A	$-1.25-5.0%	$-1.19-6.2%	$-1.12

KMTS Balance Sheet

Metric	FY26	FY25	FY24
Total Assets	$358.5M+34.6%	$266.3M+479.5%	$45.9M
Current Assets	$222.4M+0.8%	$220.7M+1380.5%	$14.9M
Cash & Equivalents	$99.7M-50.4%	$201.2M	N/A
Inventory	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A
Total Liabilities	$98.8M+20.3%	$82.1M-68.7%	$262.4M
Current Liabilities	$50.4M+56.2%	$32.3M-2.2%	$33.0M
Long-Term Debt	$42.6M+3.8%	$41.1M-3.4%	$42.5M
Total Equity	$259.7M+41.0%	$184.2M+185.1%	-$216.5M
Retained Earnings	-$651.9M-19.4%	-$546.1M-34.4%	-$406.4M

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Total Assets	$358.5M-5.5%	$379.3M+53.8%	$246.7M-7.4%	$266.3M-10.0%	$295.7M	N/A	N/A	N/A
Current Assets	$222.4M-29.2%	$314.1M+60.7%	$195.4M-11.5%	$220.7M-13.6%	$255.3M	N/A	N/A	N/A
Cash & Equivalents	$99.7M-65.8%	$291.3M+66.1%	$175.4M-12.8%	$201.2M-15.3%	$237.6M+337.1%	$54.4M-29.3%	$76.9M-23.1%	$100.0M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$98.8M+8.2%	$91.4M+10.6%	$82.6M+0.6%	$82.1M-9.1%	$90.3M	N/A	N/A	N/A
Current Liabilities	$50.4M+17.3%	$42.9M+20.1%	$35.8M+10.9%	$32.3M-15.1%	$38.0M	N/A	N/A	N/A
Long-Term Debt	$42.6M+0.9%	$42.3M+0.9%	$41.9M+0.9%	$41.5M+0.9%	$41.1M	N/A	N/A	N/A
Total Equity	$259.7M-9.8%	$288.0M+75.5%	$164.1M-10.9%	$184.2M-10.3%	$205.4M+179.6%	-$257.9M-9.0%	-$236.5M-9.3%	-$216.5M
Retained Earnings	-$651.9M-6.3%	-$613.0M-5.9%	-$578.9M-6.0%	-$546.1M-5.0%	-$520.2M	N/A	N/A	N/A

KMTS Cash Flow Statement

Metric	FY26	FY25	FY24
Operating Cash Flow	-$81.7M-5.3%	-$77.6M-7.4%	-$72.2M
Capital Expenditures	$34.9M+52.1%	$22.9M+87.6%	$12.2M
Free Cash Flow	-$116.6M-16.0%	-$100.5M-19.0%	-$84.5M
Investing Cash Flow	-$203.3M-772.1%	-$23.3M-90.6%	-$12.2M
Financing Cash Flow	$147.1M-55.5%	$330.3M+324.9%	$77.7M
Dividends Paid	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Operating Cash Flow	-$18.7M-1.9%	-$18.4M-0.1%	-$18.3M+30.2%	-$26.3M-9.2%	-$24.1M-33.7%	-$18.0M+0.3%	-$18.1M-3.2%	-$17.5M
Capital Expenditures	$9.7M-1.4%	$9.8M+34.9%	$7.3M-11.0%	$8.2M+10.5%	$7.4M+81.9%	$4.1M-8.6%	$4.4M-36.8%	$7.0M
Free Cash Flow	-$28.4M-0.8%	-$28.2M-10.0%	-$25.6M+25.6%	-$34.4M-9.5%	-$31.4M-42.5%	-$22.1M+2.0%	-$22.5M+8.3%	-$24.5M
Investing Cash Flow	-$172.7M-1057.6%	-$14.9M-101.1%	-$7.4M+9.9%	-$8.2M-11.2%	-$7.4M-66.4%	-$4.5M-0.7%	-$4.4M+37.2%	-$7.0M
Financing Cash Flow	-$185K-100.1%	$149.2M+552625.9%	-$27K+98.6%	-$1.9M-100.9%	$214.7M+180522.7%	-$119K+79.3%	-$575K-100.5%	$116.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

KMTS Financial Ratios

Metric	FY26	FY25	FY24
Gross Margin	51.4%+10.9pp	40.5%+39.2pp	1.3%
Operating Margin	-141.6%+36.2pp	-177.8%+128.0pp	-305.8%
Net Margin	-138.4%+51.9pp	-190.3%+148.1pp	-338.4%
Return on Equity	-50.7%+11.1pp	-61.8%	N/A
Return on Assets	-36.7%+6.0pp	-42.7%+162.1pp	-204.8%
Current Ratio	4.41-2.4	6.84+6.4	0.45
Debt-to-Equity	0.16-0.1	0.23	N/A
FCF Margin	-122.6%+45.5pp	-168.1%+135.6pp	-303.7%

Metric	Q4'26	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25
Gross Margin	54.8%+2.2pp	52.6%+1.9pp	50.6%+4.9pp	45.7%+1.4pp	44.3%+0.9pp	43.4%+3.8pp	39.6%+6.8pp	32.9%
Operating Margin	-137.4%+4.2pp	-141.6%-0.9pp	-140.7%+8.3pp	-149.1%+130.7pp	-279.8%-143.3pp	-136.5%-6.5pp	-130.1%+14.1pp	-144.2%
Net Margin	-135.6%+3.5pp	-139.2%+6.1pp	-145.3%-12.0pp	-133.3%+168.7pp	-302.1%-159.5pp	-142.5%-4.1pp	-138.5%+17.1pp	-155.6%
Return on Equity	-15.0%-3.1pp	-11.9%+8.1pp	-20.0%-6.0pp	-14.0%+11.3pp	-25.3%	N/A	N/A	N/A
Return on Assets	-10.8%-1.8pp	-9.0%+4.3pp	-13.3%-3.6pp	-9.7%+7.9pp	-17.6%	N/A	N/A	N/A
Current Ratio	4.41-2.9	7.32+1.9	5.47-1.4	6.84+0.1	6.72	N/A	N/A	N/A
Debt-to-Equity	0.16+0.0	0.15-0.1	0.26+0.0	0.23+0.0	0.20	N/A	N/A	N/A
FCF Margin	-99.1%+15.6pp	-114.7%-1.2pp	-113.5%+64.3pp	-177.8%+4.7pp	-182.5%-36.3pp	-146.2%+6.8pp	-153.0%+39.0pp	-192.0%

Similar Companies

Pulse Biosciences Inc PLSE

$2.1B

Embecta Corp EMBC

$195.2M

Staar Surg STAA

$1.2B

Biolife Solutions Inc BLFS

$1.5B

Atricure ATRC

$1.8B

Frequently Asked Questions

What is KESTRA MED TECHNOLOGIES LTD's annual revenue?

KESTRA MED TECHNOLOGIES LTD (KMTS) reported $95.1M in total revenue for fiscal year 2026. This represents a 59.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is KESTRA MED TECHNOLOGIES LTD's revenue growing?

KESTRA MED TECHNOLOGIES LTD (KMTS) revenue grew by 59% year-over-year, from $59.8M to $95.1M in fiscal year 2026.

Is KESTRA MED TECHNOLOGIES LTD profitable?

No, KESTRA MED TECHNOLOGIES LTD (KMTS) reported a net income of -$131.6M in fiscal year 2026, with a net profit margin of -138.4%.

What is KESTRA MED TECHNOLOGIES LTD's EBITDA?

KESTRA MED TECHNOLOGIES LTD (KMTS) had EBITDA of -$126.0M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does KESTRA MED TECHNOLOGIES LTD have?

As of fiscal year 2026, KESTRA MED TECHNOLOGIES LTD (KMTS) had $99.7M in cash and equivalents against $42.6M in long-term debt.

What is KESTRA MED TECHNOLOGIES LTD's gross margin?

KESTRA MED TECHNOLOGIES LTD (KMTS) had a gross margin of 51.4% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.

What is KESTRA MED TECHNOLOGIES LTD's operating margin?

KESTRA MED TECHNOLOGIES LTD (KMTS) had an operating margin of -141.6% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.

What is KESTRA MED TECHNOLOGIES LTD's net profit margin?

KESTRA MED TECHNOLOGIES LTD (KMTS) had a net profit margin of -138.4% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.

What is KESTRA MED TECHNOLOGIES LTD's return on equity (ROE)?

KESTRA MED TECHNOLOGIES LTD (KMTS) has a return on equity of -50.7% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.

What is KESTRA MED TECHNOLOGIES LTD's free cash flow?

KESTRA MED TECHNOLOGIES LTD (KMTS) generated -$116.6M in free cash flow during fiscal year 2026. This represents a -16.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is KESTRA MED TECHNOLOGIES LTD's operating cash flow?

KESTRA MED TECHNOLOGIES LTD (KMTS) generated -$81.7M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.

What are KESTRA MED TECHNOLOGIES LTD's total assets?

KESTRA MED TECHNOLOGIES LTD (KMTS) had $358.5M in total assets as of fiscal year 2026, including both current and long-term assets.

What are KESTRA MED TECHNOLOGIES LTD's capital expenditures?

KESTRA MED TECHNOLOGIES LTD (KMTS) invested $34.9M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.

How much does KESTRA MED TECHNOLOGIES LTD spend on research and development?

KESTRA MED TECHNOLOGIES LTD (KMTS) invested $19.5M in research and development during fiscal year 2026.

How many shares does KESTRA MED TECHNOLOGIES LTD have outstanding?

KESTRA MED TECHNOLOGIES LTD (KMTS) had 59M shares outstanding as of fiscal year 2026.

What is KESTRA MED TECHNOLOGIES LTD's current ratio?

KESTRA MED TECHNOLOGIES LTD (KMTS) had a current ratio of 4.41 as of fiscal year 2026, which is generally considered healthy.

What is KESTRA MED TECHNOLOGIES LTD's debt-to-equity ratio?

KESTRA MED TECHNOLOGIES LTD (KMTS) had a debt-to-equity ratio of 0.16 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is KESTRA MED TECHNOLOGIES LTD's return on assets (ROA)?

KESTRA MED TECHNOLOGIES LTD (KMTS) had a return on assets of -36.7% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.

What is KESTRA MED TECHNOLOGIES LTD's cash runway?

Based on fiscal year 2026 data, KESTRA MED TECHNOLOGIES LTD (KMTS) had $99.7M in cash against an annual operating cash burn of $81.7M. This gives an estimated cash runway of approximately 15 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is KESTRA MED TECHNOLOGIES LTD's Altman Z-Score?

KESTRA MED TECHNOLOGIES LTD (KMTS) has an Altman Z-Score of 4.55, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is KESTRA MED TECHNOLOGIES LTD's Piotroski F-Score?

KESTRA MED TECHNOLOGIES LTD (KMTS) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are KESTRA MED TECHNOLOGIES LTD's earnings high quality?

KESTRA MED TECHNOLOGIES LTD (KMTS) has an earnings quality ratio of 0.62x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can KESTRA MED TECHNOLOGIES LTD cover its interest payments?

KESTRA MED TECHNOLOGIES LTD (KMTS) has an interest coverage ratio of -17.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is KESTRA MED TECHNOLOGIES LTD?

KESTRA MED TECHNOLOGIES LTD (KMTS) scores 48 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.